Prakt. Lékáren. 2016; 12(4e) [Interní Med. 2016; 18(2): 66-70]

Combination therapy of arterial hypertension – a review of actual guidelines

Barbora Nussbaumerová
Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK v Praze

The article summarizes the present oppinion on the combination treatment of arterial hypertension. The most recommended and evidencebased combinations are 1/angiotensin converting enzyme inhibitor/angiotensin receptor blocker + calcium channel blocker, 2/ angiotensinconverting enzyme inhibitor/angiotensin receptor blocker + diuretic and 3/ calcium channel blocker + diuretic. Fixed combination of 2 or 3drugs are available and recommended.

Keywords: arterial hypertension, guidelines, combination treatment

Published: September 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nussbaumerová B. Combination therapy of arterial hypertension – a review of actual guidelines. Praktické lékárenství. 2016;12(E-verze 4/16):.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R, Škodová Z, Bruthans J, et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010; 28: 2196-2203. Go to original source... Go to PubMed...
    2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertension 2013; 31: 1281-1357. Go to original source... Go to PubMed...
    3. Filipovský J, Widimský J jr, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze, verze 2012: Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58: 785-801. Go to PubMed...
    4. http://www.heartscore.org/Pages/welcome.aspx.
    5. Kettani FZ, Dragomir A, Côté R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213-220. Go to original source... Go to PubMed...
    6. Peters R, Beckett N, Forrete F, et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683-689. Go to original source... Go to PubMed...
    7. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122: 290-300. Go to original source... Go to PubMed...
    8. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
    9. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
    10. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181. Go to original source... Go to PubMed...
    11. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
    12. Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
    13. Patel A, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
    14. Dahlöf B, Devereux RB, Kjeldsen SE, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    15. Matsuzaki M, Ogihara T, Umemoto S, et al. for the Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. Journal of Hypertension 2011; 29: 1649-1659. Go to original source... Go to PubMed...
    16. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-719. Go to original source... Go to PubMed...
    17. Zoungas S, Chalmers J, Neal B, ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371: 1392-1406. Go to original source... Go to PubMed...
    18. Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014; 14: 137-145. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.